Patents Issued in December 26, 2017
-
Patent number: 9849095Abstract: Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.Type: GrantFiled: November 30, 2012Date of Patent: December 26, 2017Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Katsuyuki Inoo, Akiko Katayama, Daiki Takano
-
Patent number: 9849096Abstract: The present invention provides use of composition containing molecular dispersions of carotenoids for the prevention of neurodegenerative disorders which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits. The present invention particularly relates to the use of highly water soluble composition with enhanced bioavailability containing at least 80% by weight of total xanthophylls, out of which the trans-lutein content is 80-95% w/w; (R,R)-zeaxanthin is 14-20% w/w; (R,S)-zeaxanthin is 0.01-1% w/w and traces of other carotenoids derived from the plant extracts/oleoresin containing xanthophylls/xanthophylls esters. The present invention also provides use of the said composition in treatment of neurodegenerative disorders when co-administered along with reduced dose of Levodopa and Carbidopa.Type: GrantFiled: March 28, 2014Date of Patent: December 26, 2017Assignee: OmniActive Health Technologies LimitedInventors: Jayant Deshpande, J. Shankaranarayanan
-
Patent number: 9849097Abstract: A modified release oral dosage form comprising an internal phase containing terbutaline sulphate and a pharmaceutically acceptable excipient, dispersed in an external phase comprising pharmaceutically acceptable excipients.Type: GrantFiled: October 8, 2013Date of Patent: December 26, 2017Assignee: Jagotec AGInventors: Alain Nhamias, Nasser Beniou
-
Patent number: 9849098Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.Type: GrantFiled: December 9, 2014Date of Patent: December 26, 2017Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans AffairsInventors: Beibei Chen, Rama Mallampalli
-
Patent number: 9849099Abstract: Described herein are antimicrobial compounds identified via a high-throughput screen to identify compounds that produce anucleate cells in E. coli after cell division occurs. Compound 1 (5-nonyloxytryptamine) and its analogs are small molecule inhibitors of the nucleoid occlusion system and/or proteins that are responsible for maintaining the structure of the chromosome. The antimicrobial compounds are useful to treat bacterial infections as well as to inhibit bacterial growth.Type: GrantFiled: August 10, 2016Date of Patent: December 26, 2017Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Douglas Benjamin Weibel, Katherine Ann Hurley, Katherine Cassidy Faulkner
-
Patent number: 9849100Abstract: The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula (I) (Formula (I)), wherein R1-R9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.Type: GrantFiled: January 9, 2014Date of Patent: December 26, 2017Assignee: Kalvista Pharmaceuticals LimitedInventors: Gary Paul Cook, Garry Thomas Gwozdz, Theodore Patrick Laslo
-
Patent number: 9849101Abstract: A method for enhancing amidohydrolase activity of Fatty Acid Amide Hydrolase (FAAH) is disclosed. The method comprising administering a phenoxyacyl-ethanolamide that causes the enhanced activity. The enhanced activity can have numerous effects on biological organisms including, for example, enhancing the growth of certain seedlings.Type: GrantFiled: September 15, 2016Date of Patent: December 26, 2017Assignees: Research Foundation of the City University of New York, The Curators of the University of Missouri, University of North TexasInventors: George John, Subbiah Nagarajan, Kent Chapman, Lionel Faure, Peter Koulen
-
Patent number: 9849102Abstract: A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50% or more while not affecting a corresponding TNF-? related activity level by more than 30% comprises providing a pharmaceutical composition comprising a local anaesthetic, in particular lidocaine hydrochloride, and a pharmaceutically acceptable carrier, administering the composition intraperitoneally to said person, thereby substantially reducing the recruitment of macrophages by MCP-1 released from the endometriosis implant. Also disclosed is a corresponding pharmaceutical composition.Type: GrantFiled: May 13, 2011Date of Patent: December 26, 2017Assignee: ISIFER ABInventor: Greta Edelstam
-
Patent number: 9849103Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.Type: GrantFiled: October 6, 2015Date of Patent: December 26, 2017Inventor: Young Hee Ko
-
Patent number: 9849104Abstract: Methods and formulations to reduce elevated levels of lipids and apolipoprotein B in subjects having type IIb hyperlipidemia. Methods for preventing, delaying or regressing complications of lipid disorders, including; type IIb hyperlipidemia, NAFLD, and NASH. Methods for preventing or delaying primary and secondary cardiovascular events. Kits useful for such methods. Methods for reducing hepatic fibrosis. Methods for reducing plasma fibrinogen levels.Type: GrantFiled: January 26, 2017Date of Patent: December 26, 2017Assignee: Gemphire Therapeutics Inc.Inventors: Charles L. Bisgaier, Daniela Carmen Oniciu
-
Patent number: 9849105Abstract: Invention pertains to a free-flowing particulate powder including 2-90 wt. % of an active compound on a carrier, wherein the carrier has a D(v,0.1) of at least 100 microns, with the active compound being selected from lactylate in accordance with formula (1), Formula (1): R2-COO—[—CH(CH3)-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a glycolylate of formula (2), Formula (2): R2-COO—[—CH2-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof a lactate ester of formula (3), Formula (3): HO—CH(CH3)-COO—R2 and/or a glycolic acid ester of formula (4), Formula (4): HO—CH2-COO—R2 wherein in the above formulae R1 is selected from H, n stands for an integer with a value of 1-10, and R2 stands for a C1-C35 alkyl or alkenyl chain which may be branched or unbranched. The powder allows easy provision of the active compound to feed compositions.Type: GrantFiled: July 3, 2012Date of Patent: December 26, 2017Assignee: PURAC BIOCHEM BVInventors: Symone Kok, Nikolaos Vogiatzis
-
Patent number: 9849106Abstract: The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor.Type: GrantFiled: February 3, 2017Date of Patent: December 26, 2017Assignee: Zafgen, Inc.Inventors: Thomas E. Hughes, James E. Vath
-
Patent number: 9849107Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.Type: GrantFiled: January 11, 2016Date of Patent: December 26, 2017Assignee: SEQUOIA PHARMACEUTICALS, INC.Inventors: Michael Eissenstat, Dehui Duan
-
Patent number: 9849108Abstract: A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor. The pharmacological effect may be produced by reception of tetrahydrocannabinol, cannabidiol, or mixtures thereof. The composition may also include ethanol, flavoring agents, and aromatherapy agents. The composition is deliverable to a user via vaporization. A method is provided for creating a pharmacological effect using the composition.Type: GrantFiled: May 2, 2016Date of Patent: December 26, 2017Inventor: Stephen C. Perry
-
Patent number: 9849109Abstract: Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.Type: GrantFiled: February 23, 2015Date of Patent: December 26, 2017Assignee: AMIRA PHARMACEUTICALS, INC.Inventors: Jeffrey Roger Roppe, Timothy Andrew Parr, Nicholas Simon Stock, Deborah Volkots, John Howard Hutchinson
-
Patent number: 9849110Abstract: The present specification discloses compositions comprising a pharmaceutical composition to reduce or maintain LDL and/or cholesterol levels in an individual and a plurality of therapeutic compounds to increase or maintain HDL levels in an individual. The present specification also discloses a treatment protocol wherein a pharmaceutical composition is administered to an individual on a schedule wherein the pharmaceutical composition is provided for a period of time and then not provided to the individual and this treatment protocol is repeated for the term of the individual's treatment.Type: GrantFiled: November 30, 2016Date of Patent: December 26, 2017Assignee: Biocopea LimitedInventors: John Brew, Robin Mark Bannister
-
Patent number: 9849111Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.Type: GrantFiled: December 19, 2016Date of Patent: December 26, 2017Assignee: iCeutica Pty Ltd.Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
-
Patent number: 9849112Abstract: Pyrrole compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Method for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.Type: GrantFiled: September 29, 2016Date of Patent: December 26, 2017Assignee: viDA Therapeutics Inc.Inventor: Dale R. Cameron
-
Patent number: 9849113Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.Type: GrantFiled: March 1, 2017Date of Patent: December 26, 2017Assignee: Allergan, Inc.Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
-
Patent number: 9849114Abstract: Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient. Kits including compositions of oxymetazoline suitable for topical application, for the treatment of fecal incontinence.Type: GrantFiled: May 31, 2016Date of Patent: December 26, 2017Assignee: RDD Pharma Ltd.Inventors: Nir Barak, Howard Lawrence Rice
-
Patent number: 9849115Abstract: Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: GrantFiled: August 22, 2014Date of Patent: December 26, 2017Inventor: Vasilios Voudouris
-
Patent number: 9849116Abstract: Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example, dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.Type: GrantFiled: October 8, 2015Date of Patent: December 26, 2017Assignee: Knopp Biosciences LLCInventors: Michael E. Bozik, Valentin Gribkoff, Thomas Petzinger, Jr.
-
Patent number: 9849117Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.Type: GrantFiled: January 4, 2017Date of Patent: December 26, 2017Assignee: Novartis AGInventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
-
Patent number: 9849118Abstract: Disclosed in the present invention is a protein tyrosine phosphatase inhibitor. The preparation method therefor is: extracting the crude product from the Isaria Fumosorosea Wize solid or liquid fermentation broth using ethyl acetate, ethanol, methanol, or a mixed solvent of chloroform and methanol; separating the obtained extract using column chromatography on silica gel; and obtaining the target product. The inhibitor can be used to prepare pharmaceutical compositions for treating and preventing diabetes, obesity and cancers.Type: GrantFiled: May 7, 2013Date of Patent: December 26, 2017Assignee: Heibei UniversityInventors: Duqiang Luo, Jun Zhang, Zhiqin Liu
-
Patent number: 9849119Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.Type: GrantFiled: March 29, 2017Date of Patent: December 26, 2017Assignee: TREVENA, INC.Inventors: Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, Catherine C. K. Yuan
-
Patent number: 9849120Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.Type: GrantFiled: December 9, 2016Date of Patent: December 26, 2017Assignees: Incyte Holdings Corporation, Incyte CorporationInventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Ke Zhang
-
Patent number: 9849121Abstract: An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided.Type: GrantFiled: October 10, 2014Date of Patent: December 26, 2017Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventor: Masayo Higashiyama
-
Patent number: 9849122Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.Type: GrantFiled: April 29, 2016Date of Patent: December 26, 2017Assignee: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
-
Patent number: 9849123Abstract: Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.Type: GrantFiled: August 17, 2017Date of Patent: December 26, 2017Assignee: 442 Ventures, LLCInventor: J. Mark Jackson
-
Patent number: 9849124Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: October 16, 2015Date of Patent: December 26, 2017Assignee: Purdue Pharma L.P.Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 9849125Abstract: Described herein are abuse deterrent oral pharmaceutical compositions, methods for making the same, and methods of treatment using such compositions. In particular, oral pharmaceutical compositions that mitigate the risk of overingestion of one or more active pharmaceutical ingredients are described.Type: GrantFiled: November 2, 2016Date of Patent: December 26, 2017Assignee: Banner Lifie Sciences LLCInventors: Chue Hue Yang, Tatyana Dyakonov, Nashwa El-Gendy, Jason M Vaughn, Justin R Hughey
-
Patent number: 9849126Abstract: The present disclosure describes a sterile formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, and antifungal, and an optional anti-inflammatory in a thick, otic carrier. In one embodiment, the sterilization comprises e-beam irradiating ingredients the formulation while heat-sterilizing other ingredients before combining under sterile condition.Type: GrantFiled: April 25, 2015Date of Patent: December 26, 2017Assignee: Entrx LLCInventors: Matthew Branch, Vance Oglesbee
-
Patent number: 9849127Abstract: The present invention relates to a pharmaceutical composition comprising a compound of formula (I) and methods of treating or preventing cell proliferation disorders comprising administering to a subject a therapeutically active amount or a preventive amount of such a compound.Type: GrantFiled: May 14, 2014Date of Patent: December 26, 2017Assignee: Medizinisch Hochschule HannoverInventors: Michael Heuser, Anuhar Chaturvedi, Matthias Preller
-
Patent number: 9849128Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.Type: GrantFiled: March 10, 2017Date of Patent: December 26, 2017Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins UniversityInventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon
-
Patent number: 9849129Abstract: Provided are methods of treating a variety of disorders of the skin with inhibitors of the epithelial sodium channel (ENaC). The inhibitors are represented by formula (I)-(IV): where R is defined herein.Type: GrantFiled: February 18, 2016Date of Patent: December 26, 2017Assignee: PARION SCIENCES, INC.Inventors: Michael Ross Johnson, William Robert Thelin, Richard C. Boucher
-
Patent number: 9849130Abstract: Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a synergistic combination of clofazimine and metronidazole. Pharmaceutical compositions comprising clofazimine and metronidazole are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.Type: GrantFiled: February 1, 2017Date of Patent: December 26, 2017Assignee: KamTek, Inc.Inventors: Venkata M. Reddy, Wolf Prensky, Sharanjit VedBrat
-
Patent number: 9849131Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.Type: GrantFiled: November 10, 2016Date of Patent: December 26, 2017Assignee: AUTIFONY THERAPEUTICS LIMITEDInventors: Giuseppe Alvaro, Anne Decor, Stefano Fontana, Dieter Hamprecht, Charles Large, Agostino Marasco
-
Patent number: 9849132Abstract: The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related disorders.Type: GrantFiled: January 8, 2015Date of Patent: December 26, 2017Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Joseph Hendrick, Jennifer O'Brien, Gretchen Snyder, Peng Li, Lawrence P. Wennogle
-
Patent number: 9849133Abstract: The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.Type: GrantFiled: June 18, 2014Date of Patent: December 26, 2017Assignee: Eton Pharmaceuticals, Inc.Inventor: Matthew J. Buderer
-
Patent number: 9849134Abstract: A ?1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a ?1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the ?1-ADR agonist compound.Type: GrantFiled: February 18, 2015Date of Patent: December 26, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Mehrdad Shamloo, Bitna Yi, Pooneh Memar Ardestani
-
Patent number: 9849135Abstract: Disclosed herein are methods of treating or preventing a viral infection resulting from infection by a flavivirus, comprising administering to a subject a small molecule inhibitor of USP14, represented by Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, chemically-protected form, enantiomer or stereoisomer thereof, and pharmaceutical compositions comprising an effective amount of a compound of Formula (I) for use in the method.Type: GrantFiled: January 25, 2013Date of Patent: December 26, 2017Assignees: President and Fellows of Harvard College, Health Research, Inc.Inventors: Daniel J. Finley, Dilip Nag, Laura D. Kramer
-
Patent number: 9849136Abstract: A method for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor with compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is an optionally substituted thiazole, oxazole, isothiazole or isoxazole and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein.Type: GrantFiled: March 15, 2017Date of Patent: December 26, 2017Assignee: Roche Palo Alto LLCInventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
-
Patent number: 9849137Abstract: A method of treating animals includes administering water soluble granules to an animal, where the water soluble granules include meloxicam, salt forming agent operable to form a meloxicam salt, a binder, and a carrier.Type: GrantFiled: July 28, 2014Date of Patent: December 26, 2017Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Stefan Henke, Martin A. Folger, Jens Lehmann, Diana C. Keilhofer, Hans-Juergen Kroff, Nina Herz
-
Patent number: 9849138Abstract: The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzodiazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity.Type: GrantFiled: September 4, 2015Date of Patent: December 26, 2017Assignee: The Regents of the University of MichiganInventor: Gary D. Glick
-
Patent number: 9849139Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.Type: GrantFiled: November 22, 2016Date of Patent: December 26, 2017Assignee: NeuPharma, Inc.Inventors: Xiangping Qian, Yong-Liang Zhu
-
Patent number: 9849140Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human or non-human animals.Type: GrantFiled: August 19, 2015Date of Patent: December 26, 2017Assignee: ALLERGAN, INC.Inventors: Kevin S. Warner, Kristin B. Prinn, Chetan P. Pujara, Pramod Sarpotdar, John T. Trogden, Adnan K. Salameh, Guang Wei Lu
-
Patent number: 9849141Abstract: The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies.Type: GrantFiled: December 12, 2013Date of Patent: December 26, 2017Assignee: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILEInventors: Alexis M. Kalergis, Andres A. Herrada
-
Patent number: 9849142Abstract: Methods of treatment and dosage regimes using hydrophobic gel or foam compositions comprising a tetracycline antibiotic for accelerating the return of skin integrity and or in treating or alleviating a disorder including impetigo, acne, rosacea, a skin disease caused by a bacteria or a tetracycline antibiotic responsive disease, wherein the foam composition or gel is administered topically to a target area on a subject having the disorder and wherein the target area comprises an area of skin, or mucosa or an eye.Type: GrantFiled: March 14, 2013Date of Patent: December 26, 2017Assignee: Foamix Pharmaceuticals Ltd.Inventors: Dov Tamarkin, Elana Gazal, Rita Keynan, Meir Eini, David Schuz
-
Patent number: 9849143Abstract: A method for the prevention or treatment of Influenza virus infection or Adenovirus infection by administering an effective amount of a compound of Formula (I), Formula (II), or similar compound to an individual in need is provided.Type: GrantFiled: February 16, 2017Date of Patent: December 26, 2017Assignee: The Burlington HC Research Group, Inc.Inventors: Dale M. Walker, Adriana Elisa Kajon, Vernon E. Walker
-
Patent number: 9849144Abstract: Pharmaceutical compositions comprising glutamine and trehalose for treating side effects to oncology treatments are disclosed.Type: GrantFiled: August 27, 2014Date of Patent: December 26, 2017Assignee: Healios Oncology Nutrition, LLCInventor: Peter Meade Anderson